AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06425211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perineal electromyographic biofeedback
Description: Free muscle work and gross motor coordination:
Study NCT06425211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Muscular proprioceptive work: 50 Hz 300 µs
Study NCT05447455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
Study NCT05447455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic wound infiltration
Description: 40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
Study NCT01540747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol + folic acid + melatonin
Description: Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
Study NCT01540747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol + folic acid
Description: Myo-inositol (2000mg) + folic acid (200 mcg)
Study NCT05028816 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Side 1: Final layer closure with force modulating tissue bridges (FMTB)
Description: Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
Study NCT05028816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Side 1: Final layer dermal closure with poliglecaprone 25 suture
Description: Current method of wound closure
Study NCT05028816 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Side 2: Final layer closure with force modulating tissue bridges (FMTB)
Description: Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
Study NCT05028816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Side 2: Final layer dermal closure with poliglecaprone 25 suture
Description: Current method of wound closure
Study NCT06062095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI-powered computer-aided diagnosis (CADx)
Description: Real time AI will be used to diagnosis polyps found during colonoscopy.
Study NCT05240807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photon counting computed tomography (PC-CT)
Description: Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems
Study NCT04947410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP or nasal dilators
Description: CPAP = active comparator nasal dilators = placebo comparator
Study NCT04947410 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP or nasal dilators
Description: CPAP = active comparator nasal dilators = placebo comparator
Study NCT06490081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
Study NCT04972422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 is a study drug
Study NCT05491681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous delivery of allogeneic bone marrow-derived MSCs
Description: MSCs
Study NCT04966650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT)
Description: The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms.
Study NCT06199544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Comparing the effect of drugs on symptoms of PCOS
Study NCT05725824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTE hearing aid with compatible earmolds
Description: Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.
Study NCT05231278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nCLE aided RANB biospy
Description: nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
Study NCT06582199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Plasma, DNA, RNA and PBMC Sampling
Study NCT06582199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological battery tests
Description: * Short term memory: Digit span (forward and backward)~* Long term memory: Free and Cued selective reminding Test~* Language and semantic Memory : Verbal Fluency (Category and Litteral), Image Naming (DO 40)~* Praxis~* Visuo Spatial abilities: Rey-Osterrieth Complex Figure Test~* Attention and executive functions: Trail Making Test (TMT) Part A and B, Frontal Assessment Battery (FAB)~* Autonomy in daily life activities : Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), Instrumental Activities of Daily Living (IADL)~* Mood and anxiety: Hospital Anxiety and Depression Scale (HADS)~* Cognitive reserve : Cognitive Reserve Index questionnaire (CRIq)
Study NCT06311253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emoform Glic Toothpaste
Description: Daily use of Emoform Glic toothpaste twice a day during home oral hygiene
Study NCT06311253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emoform Glic Toothpaste
Description: Daily use of Emoform Glic toothpaste twice a day during home oral hygiene
Study NCT06311253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emoform Glic Mouthwash
Description: Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
Study NCT05079568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go VR headset
Description: Virtual reality programs consisting of interactive games, meditation and deep breathing exercises, and passive virtual reality experiences designed to facilitate relaxation.
Study NCT05079568 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Oculus Go VR headset
Description: Virtual reality program with two-dimensional nature video
Study NCT06418529 — intervention group
Intervention type: DRUG
Intervention: tofacitinib
Description: New index treatment of tofacitinib
Study NCT06418529 — intervention group
Intervention type: DRUG
Intervention: tumor necrosis factor inhibitors (TNFi)
Description: New index treatment of TNFi
Study NCT06418529 — intervention group
Intervention type: DRUG
Intervention: abatacept
Description: New index treatment of abatacept
Study NCT06418529 — intervention group
Intervention type: DRUG
Intervention: tocilizumab or sarilumab
Description: New index treatment of tocilizumab or sarilumab
Study NCT04621266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Home-based peer support
Description: Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
Study NCT06456853 — intervention group
Intervention type: OTHER
Intervention: Pain assesment
Description: We will ask patients about their pain and will try to asses their pain scores. Then we will ask them to which methot is more suitable for assesment.
Study NCT05772169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 300 MG [Korlym]
Description: Mifepristone tablets for once daily oral dosing
Study NCT05772169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for mifepristone
Description: Placebo tablets for once daily oral dosing
Study NCT05027958 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tuberculin Purified Protein Derivative
Description: PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
Study NCT06249152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-111, 0.015%
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
Study NCT06249152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-111, 0.030%
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
Study NCT06249152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-111, 0.075%
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
Study NCT06249152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QLS-111 vehicle ophthalmic solution
Description: Vehicle drops applied QPM for 14 days the BID for 14 days.
Study NCT06033547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Formulation F
Description: Cabotegravir Formulation F will be administered
Study NCT05725824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTE hearing aid with compatible earmolds
Description: Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.
Study NCT05752747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Massage Group
Description: Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
Study NCT05752747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ShotBlocker© Group
Description: It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
Study NCT05497297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 tablets
Description: HSK7653, tablet, oral
Study NCT05161026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bone osteodensitometry
Description: Evaluation of bone osteodensitometry
Study NCT06033547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Formulation G
Description: Cabotegravir Formulation G will be administered
Study NCT06056518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based risk prediction for kidney graft loss
Description: Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.
Study NCT06432543 — intervention group
Intervention type: DEVICE
Intervention: polyethylene
Description: No intervention as this is an observational study
Study NCT06474325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention via mobile application
Description: Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
Study NCT06786689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine (AZA)
Description: weekly single dose of tab azathioprine 300mg
Study NCT06786689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: oral Betamethsone 5mg for 2 consecutive days weekly
Study NCT06784089 — intervention group
Intervention type: OTHER
Intervention: Geriatric Nutrition Risk Index
Description: GNRI will be calculated from the formula \[1.489 X albumin (g/L)\] + \[41.7 (weight/ideal weight)\]. If the patient's weight is more than their ideal weight, the weight/ideal weight ratio will be accepted as 1. The ideal weight will be calculated for men with the formula \[(Height-100) -(Height-150/4)\], for women with the formula \[(Height-100) -(Height-150/2.5)\]. According to the results, patients will be determined as no risk (GNRI > 98), low risk (92-98), severe/moderate risk (GNRI \< 92).
Study NCT06784089 — intervention group
Intervention type: OTHER
Intervention: visual analog scale
Description: During the VAS evaluation, the patient will be asked to indicate the location of the pain on a 100 cm long scale where 0: no pain, 100: maximum pain, and the value shown by the patient will be recorded.
Study NCT06786429 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gardasil 9 vaccine
Description: Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.
Study NCT06786429 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hepatitis B Virus Vaccine(HBV)
Description: Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.
Study NCT06322277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological sample
Description: Confermation of type of infection with RT-PCR.
Study NCT04886297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mega Resveratrol® capsules
Description: Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.
Study NCT04886297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mega Resveratrol® Placebo capsules
Description: Mega Resveratrol® Placebo capsules
Study NCT05582876 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiopharmaceutical 68Ga-PSMA-11 PET/CT
Description: The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
Study NCT06786429 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Therapy
Description: Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.
Study NCT05165719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corona-T-test
Description: Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells
Study NCT05456243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Description: Single intra-arterial infusion of 1 x 10\^5 cells/kg
Study NCT05456243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Description: Single intra-arterial infusion of 5 x 10\^5 cells/kg infused over 5 minutes
Study NCT06785701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Gastrointestinal Endoscopy
Description: After Entering to emergency based on time of hemetemsis and based on presentation to ER , patient will be assessed and based on hemodyamic stability patient can be taken Early/Emergent endoscopy.
Study NCT06785701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Gastrointestinal Endoscopy
Description: After Entering to emergency based on time of hemetemsis and based on presentation to ER , patient will be assessed and based on hemodyamic stability patient can be taken Early/Emergent endoscopy.
Study NCT06782646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Participants will take purified berberine (500 mg orally twice a day) for 12 weeks.
Study NCT06782646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.
Study NCT05373823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySmartSkin enhancement
Description: Focuses on MySmartSkin web application/intervention including enhancements using stakeholder collaboration and input
Study NCT06229041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab ＋Immunotherapy
Description: Camrelizumab was used in preoperative treatment.
Study NCT05883163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimit Activator 1
Description: The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
Study NCT05373823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational webpage on Skin Self-Examination
Description: Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
Study NCT05373823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assess implementation outcomes
Description: A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
Study NCT06783205 — intervention group
Intervention type: OTHER
Intervention: Restriction of the Dominant Hand Due to Splint Use
Description: This study aimed to assess whether the non-dominant hand function changes in patients using splints or casts on their dominant hand during the tissue healing period.
Study NCT06787807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: sleeve gastrectomy
Study NCT06786533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-FLT3 CAR-T cells
Description: Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.
Study NCT06786377 — intervention group
Intervention type: GENETIC
Intervention: saliva sampling
Description: saliva sampling
Study NCT06785298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/carbidopa
Description: A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD
Study NCT06785298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines
Study NCT06782698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: The home-based program follows the National recommendations on Physical Exercise for Cancer Patients \[Bruno RC, 2023\]. It is logbook-guided and technology-enabled.~It consists of:~* Two initial supervised explanatory sessions, in the Physic and Rehabilitation Medicine Gym of our institution.~* Followed by 2 muscular training sessions + 3 additional periods of aerobic exercise per week in their home environment until the end of neoadjuvant treatment. Patients are given a logbook with instructions and a sports bracelet for heart rate monitoring.~The training sessions will be monitored by smartwatch heart rate measurements and self-notion of effort according to Borg Categorization \[Borg GA, 1982\] and recorded by the participants in the Mi Fitness application or an Exercise Diary.\[Nilsen TS, 2018\]
Study NCT06782698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of Healthy Physical Activity
Description: The short counseling consists of at least one opportunistic talk for promotion of physical activity, taking up to 5 minutes, during the Medical Oncology appointment or during Physical Assessments at T0. It should follow the instructions of the Portuguese Directorate-General of Health, Short Counselling for the Promotion of Physical Activity, including the delivery of a Physical Activity Guide plus a Auxiliar of Decision or a Plan of Action or Maintenance.\[Mendes R, 2020\] All patients will receive a Guide about Nutrition for Cancer Patients \[Capela AM, 2023\] and may be offered Nutritional, Psychological or other additional consultations according to clinical judgement of the Medical Oncologist.
Study NCT06782698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of Healthy Physical Activity
Description: The short counseling consists of at least one opportunistic talk for promotion of physical activity, taking up to 5 minutes, during the Medical Oncology appointment or during Physical Assessments at T0. It should follow the instructions of the Portuguese Directorate-General of Health, Short Counselling for the Promotion of Physical Activity, including the delivery of a Physical Activity Guide plus a Auxiliar of Decision or a Plan of Action or Maintenance.\[Mendes R, 2020\] All patients will receive a Guide about Nutrition for Cancer Patients \[Capela AM, 2023\] and may be offered Nutritional, Psychological or other additional consultations according to clinical judgement of the Medical Oncologist.
Study NCT06785753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation Solution
Description: normal saline will be used as irrigation solution